Loading clinical trials...
Loading clinical trials...
An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Interventions
Dexpramipexole Dihydrochloride
Locations
23
United States
Research Site US-10001-017
Conway, Arkansas, United States
Research Site US-10001-008
Newport Beach, California, United States
Research Site US-10001-022
Northridge, California, United States
Research Site US-10001-016
Westminster, California, United States
Research Site US-10001-030
Orlando, Florida, United States
Research Site 10001-032
Champaign, Illinois, United States
Start Date
July 9, 2024
Primary Completion Date
October 1, 2025
Completion Date
December 1, 2025
Last Updated
May 14, 2025
NCT05746039
NCT07190209
NCT07307781
NCT07073950
NCT07509606
NCT07451977
Lead Sponsor
Areteia Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions